These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 33890704)

  • 1. Effect of deglucuronidation on the results of the Basel phenotyping cocktail.
    Bachmann F; Duthaler U; Krähenbühl S
    Br J Clin Pharmacol; 2021 Dec; 87(12):4608-4618. PubMed ID: 33890704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
    Duthaler U; Bachmann F; Suenderhauf C; Grandinetti T; Pfefferkorn F; Haschke M; Hruz P; Bouitbir J; Krähenbühl S
    Clin Pharmacokinet; 2022 Jul; 61(7):1039-1055. PubMed ID: 35570253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
    Berger B; Kaufmann P; Berse M; Treiber A; Grignaschi N; Dingemanse J
    Pharmacol Res Perspect; 2023 Oct; 11(5):e01143. PubMed ID: 37800597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
    Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
    Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
    Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
    Mohamed MF; Feng T; Enejosa JV; Fisniku O; Othman AA
    J Clin Pharmacol; 2020 Jan; 60(1):86-95. PubMed ID: 31378969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
    Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
    Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver Cirrhosis.
    Duthaler U; Bachmann F; Ozbey AC; Umehara K; Parrott N; Fowler S; Krähenbühl S
    Clin Pharmacokinet; 2023 Aug; 62(8):1141-1155. PubMed ID: 37328712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
    Pai SM; Yamada H; Murata H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput assay to simultaneously evaluate activation of CYP3A and the direct and time-dependent inhibition of CYP3A, CYP2C9, and CYP2D6 using liquid chromatography-tandem mass spectrometry.
    Yumoto Y; Endo T; Harada H; Kobayashi K; Nakabayashi T; Abe Y
    Xenobiotica; 2024 Feb; 54(2):45-56. PubMed ID: 38265764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.
    Stage TB; Graff M; Wong S; Rasmussen LL; Nielsen F; Pottegård A; Brøsen K; Kroetz DL; Khojasteh SC; Damkier P
    Br J Clin Pharmacol; 2018 Mar; 84(3):510-519. PubMed ID: 29105855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Ghosh A; Pu J; Carayannopoulos LN; Li Y
    J Clin Pharmacol; 2024 Aug; 64(8):984-992. PubMed ID: 38563070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
    Blakey GE; Lockton JA; Perrett J; Norwood P; Russell M; Aherne Z; Plume J
    Br J Clin Pharmacol; 2004 Feb; 57(2):162-9. PubMed ID: 14748815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.
    van der Heijden LT; Opdam FL; Beijnen JH; Huitema ADR
    Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):407-418. PubMed ID: 38689161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a bupropion, dextromethorphan, and omeprazole cocktail for simultaneous phenotyping of cytochrome P450 2B11, 2D15, and 3A12 activities in dogs.
    Martinez SE; Jimenez TEP; Court MH
    Am J Vet Res; 2024 Jul; 85(7):. PubMed ID: 38718826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis.
    Agachi S; Beloukhova M; Mould D; Lemak M; Grishin S; Samsonov M
    Br J Clin Pharmacol; 2024 Jul; ():. PubMed ID: 38984761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutrimetric Validation of Solanidine as Dietary-Derived CYP2D6 Activity Marker In Vivo.
    Müller JP; Sarömba J; Ziegler P; Tremmel R; Rengelshausen J; Schaeffeler E; Just KS; Schwab M; Kraus T; Stingl JC
    Clin Pharmacol Ther; 2024 Feb; 115(2):309-317. PubMed ID: 37971251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of acute hydrogen sulfide poisoning on cytochrome P450 isoforms activity in rats.
    Wang X; Chen M; Chen X; Ma J; Wen C; Pan J; Hu L; Lin G
    Biomed Res Int; 2014; 2014():209393. PubMed ID: 24790991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a case-control pharmacokinetic study.
    Neyshaburinezhad N; Rouini M; Shirzad N; Esteghamati A; Nakhjavani M; Namazi S; Ardakani YH
    MethodsX; 2020; 7():100853. PubMed ID: 32337164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.
    Dunvald AD; Søltoft K; Sheetal E; Just SA; Frederiksen IEB; Nielsen F; Olsen DA; Madsen JS; Hendricks O; Stage TB
    Eur J Clin Pharmacol; 2023 Dec; 79(12):1687-1698. PubMed ID: 37831074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.